Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia

Cancer Chemotherapy and Pharmacology, 06/05/2012

Concurrent use of proton pump inhibitors (PPIs) or H2 blockers did not affect the pharmacokinetics and efficacy of nilotinib in patients with positive (Ph+) chronic myeloid leukemia in chronic phase (Ph+ CML–CP).

Print Article Summary Cat 2 CME Report